Centessa Pharmaceuticals plc (NASDAQ:CNTA – Get Rating) shares gapped up before the market opened on Friday . The stock had previously closed at $4.87, but opened at $5.05. Centessa Pharmaceuticals shares last traded at $5.35, with a volume of 1,566 shares changing hands.
A number of brokerages recently issued reports on CNTA. BMO Capital Markets began coverage on shares of Centessa Pharmaceuticals in a research note on Thursday, June 16th. They issued an “outperform” rating and a $19.00 price target for the company. Jefferies Financial Group lowered shares of Centessa Pharmaceuticals from a “buy” rating to a “hold” rating and set a $4.00 price target for the company. in a research note on Friday, June 3rd. The Goldman Sachs Group dropped their price target on shares of Centessa Pharmaceuticals from $12.00 to $8.00 and set a “neutral” rating for the company in a research note on Tuesday, May 24th. Finally, Morgan Stanley dropped their price target on shares of Centessa Pharmaceuticals from $19.00 to $15.00 and set an “overweight” rating for the company in a research note on Tuesday, May 24th.
The company has a market cap of $482.43 million and a price-to-earnings ratio of -2.17. The company has a debt-to-equity ratio of 0.16, a current ratio of 21.37 and a quick ratio of 21.37. The firm’s fifty day moving average price is $5.51 and its 200-day moving average price is $8.13.
In other Centessa Pharmaceuticals news, CEO Saurabh Saha purchased 10,000 shares of the company’s stock in a transaction on Friday, June 24th. The shares were purchased at an average cost of $4.63 per share, for a total transaction of $46,300.00. Following the completion of the transaction, the chief executive officer now owns 38,000 shares in the company, valued at $175,940. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Antoine Yver sold 20,222 shares of the business’s stock in a transaction dated Tuesday, May 17th. The stock was sold at an average price of $5.42, for a total value of $109,603.24. Following the sale, the executive vice president now owns 813,675 shares in the company, valued at approximately $4,410,118.50. The disclosure for this sale can be found here. Corporate insiders own 9.09% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of CNTA. Medicxi Ventures Management Jersey Ltd raised its holdings in Centessa Pharmaceuticals by 1.1% during the 4th quarter. Medicxi Ventures Management Jersey Ltd now owns 18,123,892 shares of the company’s stock worth $204,075,000 after buying an additional 200,000 shares during the period. OUP Management Co. LLC acquired a new stake in Centessa Pharmaceuticals during the 4th quarter worth about $26,370,000. American Century Companies Inc. raised its holdings in Centessa Pharmaceuticals by 39.7% during the 4th quarter. American Century Companies Inc. now owns 517,123 shares of the company’s stock worth $5,823,000 after buying an additional 146,831 shares during the period. Compagnie Lombard Odier SCmA raised its holdings in Centessa Pharmaceuticals by 111.6% during the 4th quarter. Compagnie Lombard Odier SCmA now owns 5,820 shares of the company’s stock worth $66,000 after buying an additional 3,070 shares during the period. Finally, Ensign Peak Advisors Inc raised its holdings in Centessa Pharmaceuticals by 19.9% during the 4th quarter. Ensign Peak Advisors Inc now owns 343,292 shares of the company’s stock worth $3,866,000 after buying an additional 56,888 shares during the period. Hedge funds and other institutional investors own 95.72% of the company’s stock.
About Centessa Pharmaceuticals (NASDAQ:CNTA)
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B.
- Get a free copy of the StockNews.com research report on Centessa Pharmaceuticals (CNTA)
- Accolade Moves Higher But Growth Is Slowing
- ZIM Integrated Shipping Services (ZIM): Don’t Miss This Dividend
- RH Gives Good Reason To Get Defensive
- Why Rio Tinto Group (RIO) Is An Undervalued Opportunity
- Guidewire Software Stock is Set to Rebound
Receive News & Ratings for Centessa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centessa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.